Repligen has agreed to acquire BioLife Solutions in a deal valued at about $1.5 billion, aiming to expand its cell therapy business. Multiple outlets report that the transaction is structured as a stock-and-cash offer. The acquisition would add BioLife’s products and capabilities, which are linked to supporting cell therapy and manufacturing processes, to Repligen’s existing portfolio.
While the articles do not provide additional deal terms beyond the headline value and consideration mix, they consistently describe the strategic rationale as strengthening Repligen’s position in the cell therapy market. The coverage also characterizes the agreement as a significant expansion for Repligen, reflecting its focus on serving customers involved in cell therapy production and related workflows.
The deal’s final closing is subject to standard conditions for transactions of this type, including regulatory approvals and other customary approvals, though the provided summaries focus primarily on the acquisition announcement and overall price.
